Pharmaceutical services on treatment outcomes and economic value in intensive care unit patients:a systematic review
AIM To evaluate the treatment outcomes and economic value of pharmaceutical services for intensive care unit(ICU)patients,and to provide a methodological reference for subsequent research.METHODS Data from CNKI,Wanfang,VIP,PubMed,Embase,and Cochrane Library databases were retrieved from inception to November 2022.All original studies examining the effectiveness and economic evaluation of pharmaceutical services for ICU patients were included.A systematic review of their research methods,health outcome indicators,and economic indicators was conducted.RESULTS A total of 20 articles were ultimately included,with a sample size of 100 to 500 cases in 10 studies(50.00％)and a study period of less than 12 months in 14 studies(70.00％).There were 2 case-control studies,9 cohort studies,and 9 studies without a control group.The common treatment-related indicators were the incidence of adverse reactions(n=3,15.00％)and drug-related problems(n=3,15.00％).All studies consistently demonstrated the beneficial effects of pharmaceutical services on treatment outcomes.The most frequently used economic indicator was medication costs(n=9,45.00％).The results showed that pharmaceutical services can reduce medication treatment costs and hospitalization expenses,but may increase pharmacist labor costs.6 studies conducted cost-benefit analyses,revealing that the cost-benefit ratio of pharmaceutical services for ICU patients ranged from 1.55∶1 to 25∶1.The quality score of health economics evaluations was 62.00±8.41.CONCLUSIONS Pharmaceutical services can enhance the therapeutic effectiveness and reduce the cost of treatment for ICU patients,demonstrating a positive cost-benefit ratio.However,the quality of subsequent studies needs to be further improved.
intensive care unit patientpharmaceutical serviceeconomic evaluationsystematic review
国家科技期刊平台
NSTL
万方数据
